Lv1
20 积分 2024-08-07 加入
circ＿EPHB4协同YTHDF3通过N6-甲基腺苷依赖性稳定Wnt3促进胶质瘤进展
1小时前
已完结
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
2个月前
已完结
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
4个月前
已完结
Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study
5个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
6个月前
已完结
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial
6个月前
已完结
皖公网安备34019202002308
